Invokana Patients Seek to Consolidate in Multidistrict Litigation

On Sept. 22, 2016 patients who suffered kidney failure, ketoacidosis, or a heart condition after taking the popular type 2 diabetes medications Invokana and Invokamet requested that the Judicial Panel on Multidistrict Litigation consolidate at least 56 lawsuits in New Jersey federal court.

Patients across the country have filed lawsuits against Janssen Pharmaceuticals, Johnson & Johnson, and their related corporate entities, claiming that the drug companies failed to warn patients and physicians about the dangerous side effects of Invokana and Invokamet.

Although Invokana, Invokamet, and other SGLT2 inhibitors (such as Farxiga and Xigduo XR) have only been on the market for a short time, a significant number of patients already have experienced severe adverse events after taking these medications. Because of this, the Food and Drug Administration (FDA) announced in June 2016 that it was strengthening the warning labels of SGLT2 inhibitors to include information about acute kidney injury and how to minimize the risk for developing the condition.

Previously, in May 2015, the FDA issued a drug safety announcement and label revision to warn that Invokana and other SGLT2 inhibitors can lead to ketoacidosis, a potentially life-threatening condition in which dangerous levels of acid build up in the body.

Schlichter Bogard & Denton is currently investigating claims on behalf of patients who have suffered from kidney failure, ketoacidosis or myocardial infarction after taking Invokana, Invokamet or other SGLT2 inhibitors. Contact Schlichter Bogard & Denton at 1-800-873-5297 or for more information and to find out if you may be entitled to compensation.